Unaudited Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statements of Profit or Loss 3 Interim Condensed Consolidated Statements of Comprehensive Income 4 Interim Condensed Consolidat

Quarterly Report BioNTech SE for the Three And Six Months Ended June 30, 2022

Unaudited Interim Condensed Consolidated Financial Statements

Operating and Financial Review and Prospects

Unaudited Interim Condensed Consolidated Financial Statements

Interim Condensed Consolidated Statements of Profit or Loss

The accompanying notes form an integral part of these interim consolidated financial statements.

Interim Condensed Consolidated Statements of Comprehensive Income

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.

Interim Condensed Consolidated Statements of Financial Position

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.

Interim Condensed Consolidated Statements of Changes in Stockholders' Equity

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.

Interim Condensed Consolidated Statements of Cash Flows

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.

Selected Explanatory Notes to the Unaudited Interim Condensed Consolidated Financial Statements

1Corporate Information

BioNTech SE is a limited company incorporated and domiciled in Germany. The registered office is located in Mainz, Germany (An der Goldgrube 12, 55131 Mainz). The accompanying unaudited interim condensed consolidated financial statements present the financial position and the results of operation of BioNTech SE and its subsidiaries and have been prepared on a going concern basis in accordance with the International Financial Reporting Standards, or IFRS as issued by the International Accounting Standards Board, or IASB. References to the "Company", "BioNTech", "Group", "we", "us" and "our" refer to BioNTech SE and its consolidated subsidiaries.

We are a fully integrated global biotechnology company specializing in the development of novel medicines at the intersection of immunology and synthetic biology. Since our founding in 2008, we have focused on harnessing the power of the immune system to address human diseases with unmet medical need and major health burden. Our fully-integrated model combines decades of research in immunology, translational drug discovery and development, a technology agnostic innovation engine, GMP manufacturing, and commercial capabilities to rapidly develop and commercialize potential vaccines and therapies to address a range of serious indications on a global scale. We have built a broad toolkit across multiple technology platforms, including a diverse range of potentially first-in-class therapeutic approaches. This includes mRNA vaccines, cell and gene therapies, targeted antibodies, small molecule immunomodulators, Ribologicals, and next generation immunomodulators.

In February 2022, BioNTech Innovation GmbH, Mainz, Germany, was established and is a wholly owned consolidated subsidiary of BioNTech SE.

In June 2022, at the Annual General Meeting, or AGM, our shareholders voted to reappoint Helmut Jeggle as a member of the Supervisory Board and appointed two additional Supervisory Board members, Prof. Dr. Anja Morawietz and Prof. Dr. Rudolf Staudigl. In a meeting following the AGM, the Supervisory Board re-elected Helmut Jeggle as its Chairman. All three members will serve in their roles until the 2026 AGM.

Our unaudited interim condensed consolidated financial statements as of and for the three and six months ended June 30, 2022 were authorized for issuance in accordance with a resolution of the audit committee on August 8, 2022.

2Basis of Preparation, Significant Accounting Policies and further Accounting Topics

Basis of Preparation and Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements as of and for the three and six months ended June 30, 2022 have been prepared in accordance with International Accounting Standard (IAS) 34 Interim Financial Reporting.

The unaudited interim condensed consolidated financial statements do not include all the information and disclosures required in the consolidated financial statements, and should be read in conjunction with our audited consolidated financial statements and accompanying notes included in our Annual Report on Form 20-F as of and for the year ended December 31, 2021.

We prepare and present our unaudited interim condensed consolidated financial statements in Euros and round numbers to millions of Euros. Accordingly, numerical figures shown as totals in some tables may not be exact arithmetic aggregations of the figures that preceded them and figures presented in the explanatory notes may not add up to the rounded arithmetic aggregations.

The unaudited interim condensed consolidated financial statements as of and for the three and six months ended June 30, 2022 include BioNTech SE and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Significant Accounting Judgments, Estimates and Assumptions

The preparation of the unaudited interim condensed consolidated financial statements requires our management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the accompanying disclosures. This includes but is not limited to the judgment described as "Pfizer Agreement Characteristics" in the notes to our audited consolidated financial statements as of and for the year ended December 31, 2021. In order to determine our share of the collaboration partner's gross profits, we used certain information from the collaboration partner, including revenues from the sale of products, some of which is based on preliminary data shared

between the partners. These estimated figures may change in future periods as we receive final data from our collaboration partner. Those changes in our share of the collaboration partner's gross profit are recognized prospectively as a change in estimates. Our management continually evaluates judgments and estimates, including such related to the fair value measurement of derivatives, revenues and expenses. Management bases its judgments and estimates on parameters available when the unaudited interim condensed consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond our control. Such changes are reflected in the assumptions when they occur.

Significant Accounting Policies

The accounting policies adopted in the preparation of the unaudited interim condensed consolidated financial statements are consistent with those followed in the preparation of our audited consolidated financial statements as of and for the year ended December 31, 2021, except for income taxes which are accounted for using the expected annual tax rate in our unaudited interim condensed consolidated financial statements (see Note 5). Certain policies have been described further below due to the activities related to and the transactions occurred during the three and six months ended June 30, 2022.

Foreign Exchange Forward Contracts

Effects from foreign exchange forward contracts are either shown as other operating income or expenses on a cumulative basis and might switch between those two positions during the year-to-date reporting periods.

Standards Applied for the First Time

The IFRS standards applied for the first time as of January 1, 2022, as disclosed in the notes to the audited consolidated financial statements as of and for the year ended December 31, 2021, had no impact on our unaudited interim condensed consolidated financial statements as of and for the three and six months ended June 30, 2022.

Operational Impacts of COVID-19

As we advance our clinical programs, we are in close contact with our principal investigators and clinical sites, and are assessing the impact on the clinical trials, expected timelines and costs on an ongoing basis. For certain programs, including BNT111, BNT113, BNT122, BNT141 and BNT142 (RiboMabs), BNT151 and BNT152 153 (RiboCytokines) and BNT161 (Influenza), delays in the commencement of trials were experienced, due to slowed patient enrollment and other delays as a result of the COVID-19 pandemic. After several months of delay to focus efforts on our COVID-19 vaccine in 2020, in 2021 we started four Phase 2 clinical trials two for our FixVac product candidates BNT111 and BNT113, one each for our iNeST program BNT122 as well as for our bispecific antibody program BNT311. In addition, we have started multiple Phase 1 clinical trials in 2021 and 2022 that include product candidates for BNT211 (CARVac), BNT221 (NEO-PTC-01, a neoantigen-based T-cell therapy), BNT151 and BNT152+153 (RiboCytokines), BNT116 (FixVac), BNT141 (RiboMab) and BNT142 (RiboMab). The delays, even though they were temporary, may negatively impact our operations and overall business by delaying further progress of these clinical trials and preclinical studies. Our operations, including research and manufacturing, could also be negatively impacted due to the potential impact of staff absences as a result of self-isolation procedures or extended illness. Such factors were evaluated and considered when preparing these unaudited interim condensed consolidated financial statements as of and for the three and six months ended June 30, 2022. We will continue to evaluate observed and potential effects of the COVID-19 pandemic.

Operational Impacts of Gas Supply Situation

We monitor the natural gas supply situation as part of our regular business continuity management and are evaluating possible additional energy supply measures. Our commercial production of our COVID-19 vaccine is currently run on natural gas, but we expect that it could be powered by alternative fuel sources without interruption, if needed. According to our most recent information and analyses, commercial mRNA manufacturing in our facilities is not expected to be impacted by a natural gas shortage, such as the current one. Nonetheless, we cannot predict with certainty the impact that a continuing or more severe natural gas shortage would have on our operations. Our R D and clinical development activities are currently dependent on gas. We are also continuously monitoring the impact on our R D and clinical development activities as well and putting measures in place to mitigate the risks. Additionally, we continue to evaluate the impacts that the energy shortage may have on our partners, including Pfizer, suppliers, and service providers however, at this time, we cannot predict the actual impact the shortage may have on these partners or the resulting impacts to us. Were any of these parties to experience significant impacts from this or any other energy shortage, we may be unable to manufacture our COVID-19 vaccine, and our business could be materially harmed. We recognize the critical importance of the continued manufacturing of our COVID-19 vaccine and manufacturing and testing of our product candidates and are proactively engaging in internal and external discussions with our

counterparties and governmental authorities to address any potential risks at an early stage to mitigate any impacts due to an energy shortage.

3Revenues from Contracts with Customers

Disaggregated information on revenues

Set out below is the disaggregation of our revenues from contracts with customers

(1) Represents sales to our collaboration partners of products manufactured by us.

During the three and six months ended June 30, 2022 and 2021, commercial revenues were recognized from the supply and sales of our COVID-19 vaccine worldwide. We are the marketing authorization holder in the United States, the European Union, the United Kingdom, Canada and other countries, and holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer Inc., or Pfizer) and other countries submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are ongoing. Pfizer has marketing and distribution rights worldwide with the exception of China, Germany and Turkey. Fosun Pharma has marketing and distribution rights in China, Hong Kong special administrative region, or SAR, Macau SAR and the region of Taiwan. The allocation of marketing and distribution rights defines territories in which the collaboration partners act as a principal.

Whenever responsibilities in the manufacturing and supply process of the COVID-19 vaccine shift and our COVID-19 vaccine is transferred, the vaccine is sold from one partner to the other. During the three and six months ended June 30, 2022, we recognized 608.3 million and 1,211.5 million of revenues, respectively, from selling drug product batches manufactured by us to our partners. During the comparative periods, three and six months ended June 30, 2021, the revenues derived from sales to collaboration partners amounted to 138.1 million and 202.0 million were recognized, respectively.

By supplying our territories during the three and six months ended June 30, 2022, we recognized 557.0 million and 1,720.1 million of revenues, respectively, from direct COVID-19 vaccine sales in Germany and Turkey. During the comparative periods, three and six months ended June 30, 2021, recognized revenues derived from those sales amounted to 1,035.6 million and 1,235.4 million, respectively. The share of gross profit that we owe our collaboration partner Pfizer based on our sales is recognized as cost of sales. During the three months ended June 30, 2022 an upfront payment of 564.4 million became due and was recognized as current contract liability in our unaudited interim condensed consolidated statements of financial position.

Based on COVID-19 vaccine sales in the collaboration partners' territories, we are eligible to receive a share of their gross profit which represents a net figure and is recognized as collaboration revenues during the commercial phase together with sales milestones that are recorded once the underlying thresholds are met. During the three months ended June 30, 2022, 1,987.4 million gross profit share was recognized as revenues. During the comparative period, three months ended June 30, 2021, 3,923.7 million gross profit share and 168.6 million of sales milestones were recognized as revenues. During the six months ended June 30, 2022, 6,574.2 million of gross profit share were recognized. During the comparative period, six months ended June 30, 2021, 5,428.4 million of gross profit share and 415.8 million of sales milestones were recognized as revenues. In order to determine our share of our collaboration partners' gross profits, we used certain information from the collaboration partners, some of which is based on preliminary data shared

between the partners and might vary once final data is available. The true-up recognized prospectively during the three and six months ended June 30, 2022 and 2021, with respect to the previous period, was not material.

Research Development Revenues from Collaborations

During the three and six months ended June 30, 2022 and 2021, research and development revenues were mainly derived from our collaborations with Sanofi S.A. and Genentech Inc., or Genentech. In addition, during the six months ended June 30, 2022, we entered into a new research, development and commercialization collaboration with Pfizer to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV). Under the terms of the agreement, an amount of 67.5 million was classified as upfront payment and recognized as contract liability in our unaudited interim condensed consolidated statements of financial position. The amount is recognized as revenues upon advancement of research and development activities.

Revenues from contracts with customers were recognized as follows

(1) Represents sales based on the share of the collaboration partners' gross profit and sales milestones.

4Income and Expenses

The cost of sales recognized during the three and six months ended June 30, 2022 and 2021 are shown in the following table

4.2Research and Development Expenses

The research and development expenses recognized during the three and six months ended June 30, 2022 and 2021 are shown in the following table

4.3General and Administrative Expenses

The general and administrative expenses recognized during the three and six months ended June 30, 2022 and 2021 are shown in the following table

4.4Other Operating Expenses

The other operating expenses recognized during the three and six months ended June 30, 2022 and 2021 are shown in the following table

The loss on derivative instruments at fair value through profit or loss related to foreign exchange forward contracts that did not qualify for hedge accounting (see Note 6).

4.5Other Operating Income

The other operating income recognized during the three and six months ended June 30, 2022 and 2021 is shown in the following table

The foreign exchange differences included in operating income primarily arose from valuing our U.S. dollar denominated trade receivables which mainly resulted from our COVID-19 collaboration with Pfizer, compensated by the foreign exchange rate effects of our U.S. dollar denominated trade payables as well as our U.S. dollar denominated other financial liabilities which mainly resulted from obligations incurred from our license agreements.

The finance income recognized during the three and six months ended June 30, 2022 and 2021 is shown in the following table

The foreign exchange differences included in finance income primarily arose from valuing our U.S. dollar denominated cash and cash equivalents.

The fair value adjustments were derived from remeasuring the derivative embedded in our convertible note (see Note 6) and are reflecting the change in the derivative's fair value related to the equity investment of Pfizer mainly derived from our share price development between contract signing and closing (see Note 8).

The finance expenses recognized during the three and six months ended June 30, 2022 and 2021 are shown in the following table

The fair value adjustments were derived from remeasuring the derivative embedded in our convertible note (see Note 6).

For the six months ended June 30, 2022 and 2021, income taxes were calculated based on the best estimate of the weighted average annual income tax rates expected for the full financial years (estimated annual effective income tax rates) on ordinary income before tax plus the tax effect of any discrete items. For the six months ended June 30, 2022 and 2021, our effective income tax rates were approximately 26.8% and 30.9%, respectively. The effective income tax rate decreased in part due to average trade tax rates in Mainz, Marburg and Idar-Oberstein decreasing from 2022 onward. During the three and six months ended June 30, 2022, current income taxes were recognized with respect to the German tax group. Deferred tax effects were recognized with respect to identified discrete items. In addition, the non-tax effective fair value measurement of the convertible note was considered as permanent difference for the six months ended June 30, 2022. As of June 30, 2022, we continue to maintain a valuation allowance against deferred tax assets of our U.S. tax group as there is not sufficient probability in terms of IAS 12 that there will be future taxable profits available against which the unused tax losses and temporary differences can be utilized.

The income taxes recognized during the three and six months ended June 30, 2022 and 2021 are shown in the following table

6Financial Assets and Financial Liabilities

Set out below is an overview of financial assets, other than cash and cash equivalents, held as of June 30, 2022 and December 31, 2021.

Equity Instruments Designated at Fair Value through Other Comprehensive Income

Equity investments generally are made in conjunction with our existing commercial partnerships. In accordance with IFRS 9 we elected to present gains and losses on our equity investments in other comprehensive income to avoid fluctuation to be disclosed in our unaudited interim condensed consolidated statements of profit or loss. During the six months ended June 30, 2022, no material gains and losses on our equity investments have occurred.

Financial Assets at Amortized Cost

Trade and other receivables slightly decreased and predominantly comprise trade receivables from our COVID-19 collaboration with Pfizer as well as our direct product sales to customers in our territory. The contractual settlement of the gross profit share has a temporal offset of more than one calendar quarter. As Pfizer's fiscal quarter for subsidiaries outside the United States differs from ours, it creates an additional time lag between the recognition of revenues and the payment receipt. Consequently, as of June 30, 2022, our trade receivables included trade receivables which related to the gross profit share for the first and second quarter of 2022. The payment settling our gross profit share for the first quarter of 2022 (as defined by the contract) was received from our collaboration partner in July 2022, subsequent to the end of the reporting period. Of our trade receivables outstanding as of June 30, 2022, we collected 5,581.1 million in cash as of July 15, 2022.

Financial Liabilities

Set forth below is an overview of financial liabilities, other financial liabilities and trade payables held as of June 30, 2022 and December 31, 2021.